| Literature DB >> 35800814 |
Zahid Khan1,2.
Abstract
A 51-year-old patient was admitted with chest pain and broad complex ventricular tachycardia. He received three consecutive direct cardioversion (DC) shocks and was commenced on amiodarone infusion via a central venous catheter or central line (CVC). He responded to treatment and normal sinus rhythm (NSR) was achieved. He had elevated troponin I and underwent coronary angiogram which initially was thought to be responsible for his ventricular tachycardia. Coronary angiogram (CAG) showed unobstructed coronary arteries. He was recently diagnosed with pheochromocytoma and was commenced on Phenoxybenzamine 10 mg two months back. He developed ventricular tachycardia (VT) again the next day that did not respond to four consecutive direct cardioversion shocks (DC) and antiarrhythmic medications. He was intubated and ventilated to terminate his VT and was transferred to the intensive care unit (ICU). He remained intubated for 48 hours and he remained in NSR, after which he was extubated. He was commenced on bisoprolol and was later stepped down to the coronary care unit (CCU). Cardiac magnetic resonance imaging (CMR) showed left ventricular non-compaction (LVNC) or possibly myocarditis in view of patient's known history of pheochromocytoma. He was discussed with surgical team at another hospital for surgical resection of the adrenal tumor and had a few further runs of VT while he was waiting to be transferred. The patient finally underwent surgical resection of the tumor and was booked for implantable cardioverter defibrillator (ICD) in view of his VT. This was an interesting case of treatment-resistant VT driven by pheochromocytoma and LVNC, and it is important to be familiar with the fact that conventional therapies may fail in these patients and may require intubation and ventilation to terminate VT storms.Entities:
Keywords: adrenal pheochromocytoma; airway intubation; alpha channel blockers; amiodarone and lidocaine; beta adrenergic blockers; direct current cardioversion; implantable cardiac defibrillator (icd); left ventricular non compaction; normal coronary angiogram; ventricular tachycardia (vt) storm
Year: 2022 PMID: 35800814 PMCID: PMC9246457 DOI: 10.7759/cureus.25483
Source DB: PubMed Journal: Cureus ISSN: 2168-8184
The trend of laboratory results for this patient during hospital admission.
| Blood test | Day 1 | Day 3 | Day 7 | Normal value |
| Hemoglobin | 123 | 132 | 127 | 133-173 g/L |
| White cell count | 15 | 12.3 | 11.6 | 3.8-11 × 109/L |
| Neutrophil | 12 | 11.2 | 9.8 | 2-7.5 × 109/L |
| C-reactive protein | 23 | 25 | 20 | 0-5 mg/L |
| Urea | 6.5 | 7.2 | 7.3 | 2.5-7.8 mmol/L |
| Creatinine | 81 | 91 | 93 | 59-104 μmol |
| Sodium | 139 | 140 | 136 | 133-146 mmol/L |
| Potassium | 4.9 | 5.2 | 4.9 | 3.5-5.3 mmol/L |
| Metanephrine | 12132 | Not checked | Not checked | 12-60 pg/mL |
| Normetanephrine | 3960 | Not checked | Not checked | 18-111 pg/mL |
| Magnesium | 0.91 | 0.95 | 0.93 | 0.65-1.05 mmol/L |
Figure 1Computerized tomography scan of chest, abdomen, and pelvis shows hepatic steatosis (arrow on the right) and left adrenal tumor (arrow on the left).
Figure 2Cardiac magnetic resonance (CMR) shows left ventricular non-compaction; dark area around the left ventricular cavity (arrow)
Figure 3Cardiac magnetic resonance imaging shows left ventricular non-compaction cardiomyopathy (arrow).
Cardiac magnetic resonance imaging findings of both left and right ventricular functions.
EDV: end-diastolic volume; ESV: end-systolic volume; EF: ejection fraction; LV: left ventricle; RV: right ventricle
| Chamber | EDV (mL) | ESV (mL) | SV (mL) | EF (%) | Mass (g) |
| LV | 195 | 81 | 114 | 58 | 159 |
| 119-203 | 33-77 | 78-134 | 57-75 | 107-187 | |
| RV | 94 | 24 | 70 | 74 | - |
| 119-219 | 32-92 | 73-141 | 50-78 | 40-96 |
Cardiac magnetic resonance imaging indexed systolic and diastolic findings.
EDVi: end-diastolic volume index; ESVi: end-systolic volume index, SVi: systolic volume index; mass-i: mass index; LV: left ventricle; RV: right ventricle
| Chamber | EDVi (mL/m2) | ESVi (mL/m2) | SVi (mL/m2) | Mass-i (g/m2) |
| LV | 96 | 40 | 56 | 79 |
| 64-100 | 17-39 | 43-67 | 57-91 | |
| RV | 47 | 12 | 35 | - |
| 63-111 | 18-46 | 39-71 | 21-49 |
Figure 4Catecholamine binding affinities and adrenoceptor actions.
The image is obtained with permission from the corresponding author (Karel Pacak) [16].
Figure 5Management of catecholamine-induced tachyarrhythmias.
The image is obtained with permission from the corresponding author (Karel Pacak) [16].